Pfizer Inc. (PFE) has a MoatMap StockRank of 98/100 based on Quality (58/100), Value (69/100), and Momentum (67/100) factor scores. The current signal is STRONG BUY. Pfizer's low quality score (Q:43) and its current business challenges, including patent cliffs and post-COVID revenue normalization, classify it as a potential turnaround play or a value trap, explicitly avoided by the Terry Smith lens.
Pfizer Inc. is a global pharmaceutical giant engaged in the research, development, manufacture, and sale of innovative medicines and vaccines across a wide array of therapeutic areas. The company's competitive moat stems from its robust R&D pipeline, extensive portfolio of blockbuster drugs, and formidable intellectual property protection, enabling it to deliver life-changing treatments worldwide. As a market leader, Pfizer leverages its global scale and distribution network to address significant unmet medical needs.
| Price | $25.90 |
| Market Cap | $147.6B |
| P/E (TTM) | 19.59 |
| P/E (Forward) | 9.04 |
| Price/Book | 1.69 |
| Return on Equity | 8.3% |
| Return on Invested Capital | 6.0% |
| Debt/Equity | 71.60 |
| Gross Margin | 74.8% |
| Operating Margin | 31.6% |
| Revenue Growth | 5.4% |
| Dividend Yield | 6.7% |
| Free Cash Flow | $12.4B |
Pfizer Inc. operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).